Sale of 3,040 Pacira BioSciences shares planned

Pacira BioSciences, Inc. (PCRX) filed a notice of proposed sale of common stock under Form 144.

Rhea-AI Filing Summary

Pacira BioSciences, Inc. (PCRX) filed a notice of proposed sale of common stock under Form 144. The filer plans to sell 3,040 shares of Pacira common stock through Fidelity Brokerage Services LLC on 08/17/2026 on the NASDAQ market, with an aggregate market value of $70,619.20 for the proposed sale. The shares to be sold were originally acquired from the issuer, including 214 shares purchased on 06/30/2022 through an Employee Stock Purchase Plan (cash) and 2,826 shares acquired on 07/01/2022 through restricted stock vesting as compensation.

Key Figures

Shares proposed to be sold: 3,040 shares Aggregate market value of proposed sale: $70,619.20 Proposed sale date: 08/17/2026 +3 more

6 metrics

Shares proposed to be sold 3,040 shares Common stock proposed for sale through Fidelity Brokerage Services LLC

Aggregate market value of proposed sale $70,619.20 Aggregate market value of 3,040 shares of common stock

Proposed sale date 08/17/2026 Date of proposed sale on NASDAQ

ESPP shares acquired 214 shares Acquired on 06/30/2022 via ESPP purchase for cash

Restricted stock vested 2,826 shares Acquired on 07/01/2022 through restricted stock vesting as compensation

ESPP acquisition date 06/30/2022 Date of ESPP purchase of 214 shares

Key Terms

Form 144, Employee Stock Purchase Plan (ESPP), restricted stock vesting

3 terms

Form 144 regulatory

"filed a notice of proposed sale of common stock under Form 144"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Employee Stock Purchase Plan (ESPP) financial

"214 shares purchased on 06/30/2022 through an Employee Stock Purchase Plan"

restricted stock vesting financial

"2,826 shares acquired on 07/01/2022 through restricted stock vesting as compensation"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Pacira BioSciences (PCRX) disclose in this Form 144 filing?

Pacira BioSciences (PCRX) discloses a proposed sale of 3,040 shares of its common stock under Form 144. The sale is to occur via Fidelity Brokerage Services LLC on 08/17/2026 on NASDAQ, with an aggregate market value of $70,619.20.

How many Pacira (PCRX) shares are proposed to be sold and at what value?

The filer proposes to sell 3,040 shares of Pacira (PCRX) common stock with an aggregate market value of $70,619.20. These shares are to be sold through Fidelity Brokerage Services LLC on the NASDAQ market.

When is the proposed sale date for the Pacira (PCRX) Form 144 shares?

The proposed sale date for the Pacira (PCRX) Form 144 shares is 08/17/2026. On that date, 3,040 shares of Pacira common stock are planned to be sold through Fidelity Brokerage Services LLC on NASDAQ.

How were the Pacira (PCRX) shares in this Form 144 originally acquired?

The shares in this Form 144 were acquired directly from Pacira (PCRX), including 214 shares via an ESPP purchase on 06/30/2022 and 2,826 shares through restricted stock vesting on 07/01/2022 as compensation.

What types of equity awards are involved in the Pacira (PCRX) Form 144 filing?

The Pacira (PCRX) Form 144 filing involves ESPP shares and restricted stock. Specifically, 214 shares came from an Employee Stock Purchase Plan and 2,826 shares from restricted stock vesting as compensation in mid-2022.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 11:54 AM Accepted by SEC EDGAR 08/17/2026 - 11:54 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001875723
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Pacira BioSciences, Inc.
SEC File Number	001-35060
Address of Issuer	2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CALIFORNIA 94005
Phone	650-242-8052
Name of Person for Whose Account the Securities are To Be Sold	SLONIN JONATHAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3040	70619.20	39861886	08/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/30/2022	ESPP Purchase	Issuer			214	06/30/2022	Cash
Common	07/01/2022	Restricted Stock Vesting	Issuer			2826	07/01/2022	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jonathan Slonin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)